EUVIMEDEUVIMED entdecken
Multizentrische Studie

Group 4 Medulloblastomas of Early Childhood Treated With High‐Dose Chemotherapy‐ and Craniospinal Irradiation‐Sparing Approach

Patricia Orduña, Rose Daynielle Cansanay, Craig Erker iD, Erin Ratterman, Mary Pat Schlosser, Rebecca Ronsley, Chantel Cacciotti, Sylvia Cheng, Juliette Hukin, Dolly Aguilera, Claire Mazewski, Vanan Magimairajan iD und 21 weitere

Pediatric Blood & Cancer · 2026-05 · 73 (5)

DOI: 10.1002/1545-5017.70181 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 13.03.2026. Verfasst von Patricia Orduña und 32 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Hematology and Bone Marrow Transplantation, Alberta Children's Hospital, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Medulloblastoma, Antineoplastic Combined Chemotherapy Protocols, Craniospinal Irradiation, Cerebellar Neoplasms. Die Arbeit nennt 24 Literaturangaben. Gefördert von: the Kid Cancer Care of Alberta Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Group 4 medulloblastoma (MB) is rare in young children. Data on craniospinal irradiation (CSI)‐sparing approaches are limited.

Methods

This multicenter study reported outcomes for patients younger than 7 years old with Group 4 MB treated with high‐dose chemotherapy (HDC) without adjuvant CSI.

Results

Thirty‐eight patients were included (26 M/12 F). Median age at diagnosis was 46.4 months (25.9–78), with 24% ≤36 months. Twenty‐four patients (63.2%) had localized disease. Fourteen (36.8%) presented with metastatic disease, and 26 (68.4%) underwent gross total resection (GTR). The most used HDC regimens were carboplatin/thiotepa (76.3%) and carboplatin/thiotepa/etoposide (21.1%). Twenty (52.6%) relapses occurred at a median 21.9 months (5–99.8) from diagnosis. Patients with upfront GTR and/or who received three cycles of HDC had better PFS ( p = 0.02 and p = 0.002, respectively). Local relapse accounted for 45%. Eighteen patients received salvage therapy with curative intent, all with radiotherapy (16 = CSI, 2 = focal). The CSI dose ranged from 18 to 36 Gy, and 43.7% received ≤23.4 Gy. Patients who underwent salvage surgery and/or chemotherapy were more likely to receive CSI ≤23.4 Gy ( p = 0.008 and p = 0.03). The 5‐year post‐relapse survival and overall survival (OS) were, respectively, 60.3% (95% confidence interval [CI]: 26.9–82) and 72.7% (95% CI: 51.9–85.7). The 5‐year CSI‐free OS was 69.7% (95% CI: 39.1–87.1).

Conclusion

High dose chemotherapy for Group 4 MB was associated with a relapse rate of 52.6%, which favorably compares to data reported with conventional chemotherapy. Salvage radiotherapy retrieved more than two‐thirds of the patients. Half of the survivors never received radiotherapy. Such an approach may represent an alternative to upfront CSI for young children with Group 4 MB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaAntineoplastic Combined Chemotherapy ProtocolsCraniospinal IrradiationCerebellar NeoplasmsChemoradiotherapyHumansFemaleChild, PreschoolMaleInfantChildSurvival RateFollow-Up StudiesNeoplasm Recurrence, LocalPrognosisEtoposideCarboplatinRetrospective StudiesCombined Modality Therapy

Stichwörter der Autor:innen

craniospinal irradiation avoidancehigh‐dose chemotherapyinfant medulloblastoma

Substanzen

EtoposideCarboplatin

Autor:innen und Institutionen

  • Section of Pediatric Hematology and Bone Marrow Transplantation, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Division of Pediatric Neurology, University of the Philippines - Philippine General Hospital, Manila, Philippines.
  • Division of Hematology/Oncology, Department of Pediatrics, IWK, Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
  • Division of Pediatric Oncology, Seattle Children's Hospital, Seattle, Washington, USA.
  • Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Pediatrics, McMaster University, London Health Sciences, London, Ontario, Canada.

ORCID-Profile: Craig Erker, Vanan Magimairajan, Vicente Santa-Maria Lopez, Stefan Rutkowski, Eric Bouffet, Lucie Lafay-Cousin

Förderung

  • the Kid Cancer Care of Alberta Foundation

Zitieren

APA

Orduña, P., Cansanay, R. D., Erker, C., Ratterman, E., Schlosser, M. P., Ronsley, R., Cacciotti, C., Cheng, S., Hukin, J., Aguilera, D., Mazewski, C., Magimairajan, V., Pillay-Smiley, N., Sait, S. F., Cluster, A., Abdelbaki, M. S., Margol, A. S., Michaiel, G., Chi, S., …, & Lafay-Cousin, L. (2026). Group 4 Medulloblastomas of Early Childhood Treated With High‐Dose Chemotherapy‐ and Craniospinal Irradiation‐Sparing Approach. Pediatric Blood & Cancer, 73(5). https://doi.org/10.1002/1545-5017.70181

Vancouver

Orduña P, Cansanay RD, Erker C, Ratterman E, Schlosser MP, Ronsley R, et al. Group 4 Medulloblastomas of Early Childhood Treated With High‐Dose Chemotherapy‐ and Craniospinal Irradiation‐Sparing Approach. Pediatric Blood & Cancer. 2026;73(5). doi:10.1002/1545-5017.70181

BibTeX
@article{Ordua2026,
  author = {Orduña, Patricia and Cansanay, Rose Daynielle and Erker, Craig and Ratterman, Erin and Schlosser, Mary Pat and Ronsley, Rebecca and Cacciotti, Chantel and Cheng, Sylvia and Hukin, Juliette and Aguilera, Dolly and Mazewski, Claire and Magimairajan, Vanan and Pillay-Smiley, Natasha and Sait, Sameer Farouk and Cluster, Andrew and Abdelbaki, Mohamed S and Margol, Ashley S and Michaiel, George and Chi, Susan and Salloum, Ralph and Harrod, Virginia and Hoffman, Lindsey and Bracher, Annalise and Senapati, Akanksha and Ramaswamy, Vijay and Zapotocky, Michal and Lopez, Vicente Santa-Maria and Doris, Kathleen and Mynarek, Martin and Rutkowski, Stefan and Lassaletta, Alvaro and Bouffet, Eric and Lafay-Cousin, Lucie},
  title = {Group 4 Medulloblastomas of Early Childhood Treated With High‐Dose Chemotherapy‐ and Craniospinal Irradiation‐Sparing Approach},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {5},
  doi = {10.1002/1545-5017.70181}
}
Kostenlos starten →